Anebulo Pharmaceuticals (ANEB) Change in Account Payables (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Change in Account Payables of -$52677.0 for Q4 2025, down 276.91% year-over-year from $29776.0 in Q4 2024, and down 113.74% quarter-over-quarter from $383364.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Change in Account Payables (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Change in Account Payables for 6 consecutive years, with -$52677.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Account Payables fell 276.91% year-over-year to -$52677.0; the TTM figure through Dec 2025 stood at $272944.0 (up 842.48% YoY), while the FY2025 annual figure was $67749.0, up 117.92% from the prior year.
- Change in Account Payables eased to -$52677.0 in Q4 2025 per ANEB's latest filing, from $383364.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $383771.0 in Q3 2021 and bottomed at -$450875.0 in Q4 2021.
- Historically, Change in Account Payables has averaged $23519.2 across 5 years, with a median of $30590.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Account Payables soared 1746.24% — and 2024, when it plunged 528.47%.
- Anebulo Pharmaceuticals' Change in Account Payables stood at -$450875.0 in 2021, then soared by 115.97% to $72008.0 in 2022, then sank by 443.39% to -$247270.0 in 2023, then surged by 112.04% to $29776.0 in 2024, then sank by 276.91% to -$52677.0 in 2025.
- Business Quant data shows ANEB's Change in Account Payables at -$52677.0 in Q4 2025, $383364.0 in Q3 2025, and -$203403.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | -52,677.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -52,677.00 |
| Dec 31, 2025 | -52,677.00 |
| Sep 30, 2025 | 383,364.00 |
| Sep 30, 2025 | 383,364.00 |
| Jun 30, 2025 | -203,403.00 |
| Jun 30, 2025 | -203,403.00 |
| Mar 31, 2025 | 145,660.00 |
| Mar 31, 2025 | 145,660.00 |
| Dec 31, 2024 | 29,776.00 |
| Dec 31, 2024 | 29,776.00 |
| Sep 30, 2024 | 95,716.00 |
| Sep 30, 2024 | 95,716.00 |
| Jun 30, 2024 | -228,494.00 |
| Jun 30, 2024 | -228,494.00 |
| Mar 31, 2024 | 66,241.00 |
| Mar 31, 2024 | 66,241.00 |
| Dec 31, 2023 | -247,270.00 |
| Dec 31, 2023 | -247,270.00 |
| Sep 30, 2023 | 31,404.00 |
| Sep 30, 2023 | 31,404.00 |